Economic burden of illness among US patients experiencing fracture nonunion

Ning Wu1
Yuan-chi Lee1
Daniel Segina2
Hallie Murray3
Teresa Wilcox1
Luke Boulanger1

1United BioSource Corporation, Lexington, MA, USA; 2Department of Orthopaedics, Holmes Regional Trauma Center, Melbourne, FL, USA; 3Biomet Spine and Bone Healing Technologies, Parsippany, NJ, USA

Introduction

Approximately 7.9 million patients sustain fractures in the United States annually, and up to 10% go on to have impaired bone healing resulting in a delayed union or a nonunion.1 The distinction between a delayed union and a nonunion has been redefined over the years. A delayed union is currently defined as a fracture that has slower than expected bone healing.2 Prior to 1998, the Food and Drug Administration (FDA) defined a nonunion as a fracture 9 months post-injury that shows no visibly
progressive signs of healing for a minimum of 3 months. In 1998, the FDA’s Orthopedics and Rehabilitation Device Advisory Panel revised the definition of a nonunion to be a fracture that shows no visibly progressive signs of healing. This new definition has no timeframe restrictions associated with the determination of a nonunion.

Not all fractures are alike, and fracture healing has been shown to vary substantially depending on the fracture location. Non-operatively treated clavicular fractures have a reported nonunion rate of 6.2%, but that rate differs by the fracture site: 8.3% for medial end fractures, 4.5% for diaphyseal fractures, and 11.5% for lateral end fractures. Scaphoid fractures have an approximate nonunion rate of 10%, but the risk of nonunion can be as high as 55% when the fracture is displaced. Moreover, depending on the specific fracture characteristics and the initial fracture management, 7%–28% of fractures of the proximal fifth metatarsal result in nonunion. Differences in vascularity at the fracture site, fracture severity, and patient comorbidities affect the ability of different fractures to heal, resulting in the different reported nonunion rates. Consequently, individualized fracture management is required to promote fracture healing.

Common methods for treating fracture nonunions include surgical repair, allografts, synthetic bone grafts, autogenous bone grafts, recombinant bone morphogenetic proteins, and amputation when other treatment options have failed to induce healing. Non-invasive therapies, including electrical bone growth stimulation (EBGS) and low-intensity pulsed ultrasound stimulation (LIPUS), are FDA regulated Class III medical devices approved for the treatment of fracture nonunions. The first EBGS device received approval for the treatment of fracture nonunions in 1979; since then three additional competitive non-invasive EBGS device systems and one LIPUS device have also received approval for the treatment of fracture nonunions. With over 30 years of clinical use, EBGS has proven to be a safe and effective treatment for the management of fracture nonunions.

In today’s health care environment, understanding the economic evaluation of different treatment options is important. In 2006, bone growth stimulation represented a $500 million market in the US for fracture management as a result of the significant economic burden associated with fracture nonunions. An economic review conducted by Kanakaris and Giannoudis reported that the average direct costs for treating humeral, femoral, and tibial fracture nonunions were £15,566, £17,200, and £16,330, respectively, in the United Kingdom in 2007. Converted to US dollars, these costs are equivalent to $31,132, $34,400, and $32,660, respectively. While existing clinical literature supports the efficacy and safety of non-invasive EBGS therapy in the treatment of fracture nonunions, the economic data supporting its use in the US is sparse. Therefore, the objective of this study was to evaluate the real-world cost-effectiveness of EBGS in the treatment of fracture nonunions. This study compares the demographic differences, clinical characteristics, and treatment patterns of patients receiving EBGS, LIPUS, or no stimulation (No-stim) treatment for the management of their fracture nonunions and the health care resource use and costs associated with these different treatment options.

**Methods**

**Data source and sample selection**

This retrospective study utilized administrative claims data from the Truven Health Analytics MarketScan Commercial Insurance Databases from October 2005 through September 2010. Patients were included in the study if they had at least one medical claim with associated diagnosis suggesting fracture nonunion (International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM]: 733.82) between July 2006 and September 2009. Patients may have had multiple medical claims with associated diagnosis codes suggesting fracture nonunion for the initial diagnosis, subsequent treatment, and follow-up visits; therefore, the date of the first such medical claim was set as the index date. Patients were required to have at least one medical claim related to the diagnosis of their fracture in the 9 months prior to the index date. Only patients with claims for fractures of the appendicular system were included. Additional inclusion criteria required patients to be between 18–64 years old on the index date (this age range represents a commercially insured patient population; patients 65 years old or older were excluded as these patients are typically insured by Medicare and Medicaid), and have a minimum of 9 months of insurance eligibility prior to and 12 months following the index date. Patients were excluded if they had claims suggesting cancer metastasis (ICD-9-CM: 198.5), malignant tumor of bone (ICD-9-CM: 170.xx), fracture nonunion, use of EBGS or LIPUS, or fractures in multiple locations during the 9 months before the index date (Figure 1).

Three cohorts were created based on the first treatment that patients received within the 12 months following the index date: EBGS, LIPUS, and No-stim. The use of EBGS was identified if a medical claim had an associated Current Procedural Terminology (CPT) code of 20974 or Healthcare...
Common Procedure Coding System (HCPCS) code of E0747. Use of LIPUS was identified if a claim had an associated CPT code of 20979 or HCPCS code of E0760. The No-stim cohort included those patients with fracture nonunion diagnosis that did not receive EBGS or LIPUS after the index date.

Study measures
Demographic parameters including age, gender, geographic region of US residence (Northeast, North Central, South, West, and unknown), and insurance plan type (health maintenance organization, preferred provider organization, comprehensive, point of service, exclusive provider organization, and consumer-directed health plans) are listed in Table 1. Comorbidities and risk factors for fracture nonunion were assessed based on medical and pharmacy claims in the 9 months before the index date. The burden of chronic diseases was measured by the Charlson Comorbidity Index (CCI). Fracture characteristics including open vs closed, fracture location, and the time between initial fracture and nonunion diagnosis were also reported. Clinical outcomes were neither reported nor available from the database for analysis.

Health care costs for the 9 months before and the 12 months after the index date were evaluated. Total health care costs included the costs associated with inpatient care, outpatient care, and medication use. Fracture-related costs included all claims associated with services required to diagnose and treat the patient’s fracture. Pharmacy-related costs were excluded from the fracture-related costs as there are no specific medications designated for the treatment of a fracture. All costs were adjusted for inflation using the Consumer Price Index and standardized to 2011 US dollars so that cost measures from different years would be comparable.

Statistical analysis
Descriptive statistics for demographics, comorbidities, treatment patterns, fracture locations, and post-index health care and fracture-related costs were compared among the three different treatment cohorts. Percentages were reported for categorical variables, while the mean and standard deviation were reported for continuous variables. A Student’s t-test was used to detect differences in age and days between initial fracture and nonunion diagnosis; a χ² test was used to detect...
Table 1  Demographics and comorbidities of the three treatment cohorts: EBGS, LIPUS and No-stim

<table>
<thead>
<tr>
<th>Treatment cohorts</th>
<th>EBGS (N = 3,430)</th>
<th>LIPUS (N = 1,434)</th>
<th>No-stim (N = 6,764)</th>
<th>P-values</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N (%)</td>
<td>N (%)</td>
<td>N (%)</td>
<td>EBGS vs LIPUS</td>
</tr>
<tr>
<td><strong>Age (years)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18–24</td>
<td>345 (10.1)</td>
<td>133 (9.3)</td>
<td>978 (14.5)</td>
<td>0.51</td>
</tr>
<tr>
<td>25–34</td>
<td>316 (9.2)</td>
<td>118 (8.2)</td>
<td>708 (10.5)</td>
<td></td>
</tr>
<tr>
<td>35–44</td>
<td>597 (17.4)</td>
<td>242 (16.9)</td>
<td>1,137 (16.8)</td>
<td></td>
</tr>
<tr>
<td>45–54</td>
<td>1,084 (31.6)</td>
<td>456 (31.8)</td>
<td>1,888 (27.9)</td>
<td></td>
</tr>
<tr>
<td>55–64</td>
<td>1,088 (31.7)</td>
<td>485 (33.8)</td>
<td>2,053 (30.4)</td>
<td></td>
</tr>
<tr>
<td><strong>Gender</strong></td>
<td></td>
<td></td>
<td></td>
<td>0.77</td>
</tr>
<tr>
<td>Male</td>
<td>1,379 (40.2)</td>
<td>583 (40.7)</td>
<td>3,350 (49.5)</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>2,051 (59.8)</td>
<td>851 (59.3)</td>
<td>3,414 (50.5)</td>
<td></td>
</tr>
<tr>
<td><strong>Insurance plan type</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Comprehensive</td>
<td>104 (3.0)</td>
<td>31 (22)</td>
<td>265 (3.9)</td>
<td></td>
</tr>
<tr>
<td>EPO</td>
<td>16 (0.5)</td>
<td>8 (0.6)</td>
<td>30 (0.4)</td>
<td></td>
</tr>
<tr>
<td>HMO</td>
<td>503 (14.7)</td>
<td>192 (13.4)</td>
<td>1,003 (14.8)</td>
<td></td>
</tr>
<tr>
<td>POS</td>
<td>339 (9.9)</td>
<td>143 (10.0)</td>
<td>584 (8.6)</td>
<td></td>
</tr>
<tr>
<td>PPO</td>
<td>2,254 (65.7)</td>
<td>995 (69.4)</td>
<td>4,542 (67.1)</td>
<td></td>
</tr>
<tr>
<td>POS w/capitation*</td>
<td>25 (0.7)</td>
<td>3 (0.2)</td>
<td>42 (0.6)</td>
<td></td>
</tr>
<tr>
<td>CDHP</td>
<td>86 (2.5)</td>
<td>28 (2.0)</td>
<td>146 (2.2)</td>
<td></td>
</tr>
<tr>
<td>Missing/unknown</td>
<td>103 (3.0)</td>
<td>34 (2.4)</td>
<td>152 (2.2)</td>
<td></td>
</tr>
<tr>
<td><strong>Region</strong></td>
<td></td>
<td></td>
<td></td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Northeast</td>
<td>481 (14.0)</td>
<td>131 (9.1)</td>
<td>640 (9.5)</td>
<td></td>
</tr>
<tr>
<td>North Central</td>
<td>769 (22.4)</td>
<td>304 (21.2)</td>
<td>1,944 (28.7)</td>
<td></td>
</tr>
<tr>
<td>South</td>
<td>1,481 (43.2)</td>
<td>739 (51.5)</td>
<td>2,744 (40.6)</td>
<td></td>
</tr>
<tr>
<td>West</td>
<td>625 (18.2)</td>
<td>223 (15.6)</td>
<td>1,309 (19.4)</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>74 (2.2)</td>
<td>37 (2.6)</td>
<td>127 (1.9)</td>
<td></td>
</tr>
<tr>
<td><strong>Charlson Comorbidity Index</strong></td>
<td></td>
<td></td>
<td></td>
<td>0.47</td>
</tr>
<tr>
<td>CCI = 0</td>
<td>2,394 (69.8)</td>
<td>1,012 (70.6)</td>
<td>5,029 (74.3)</td>
<td></td>
</tr>
<tr>
<td>CCI = 1</td>
<td>344 (10.0)</td>
<td>154 (10.7)</td>
<td>567 (8.4)</td>
<td></td>
</tr>
<tr>
<td>CCI = 2</td>
<td>443 (12.9)</td>
<td>163 (11.4)</td>
<td>685 (10.1)</td>
<td></td>
</tr>
<tr>
<td>CCI &gt; 3</td>
<td>249 (7.3)</td>
<td>105 (7.3)</td>
<td>483 (7.1)</td>
<td></td>
</tr>
<tr>
<td><strong>Comorbidities of fracture nonunion</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diabetes</td>
<td>479 (14.0)</td>
<td>183 (12.8)</td>
<td>742 (11.0)</td>
<td>0.26</td>
</tr>
<tr>
<td>Osteoporosis</td>
<td>173 (5.0)</td>
<td>66 (4.6)</td>
<td>271 (4.0)</td>
<td>0.52</td>
</tr>
<tr>
<td>Malnutrition</td>
<td>3 (0.1)</td>
<td>4 (0.3)</td>
<td>20 (0.3)</td>
<td>0.11</td>
</tr>
<tr>
<td>Anemia</td>
<td>234 (6.8)</td>
<td>121 (8.4)</td>
<td>498 (7.4)</td>
<td>0.05</td>
</tr>
<tr>
<td><strong>Risk factors of fracture nonunion</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Smoking</td>
<td>7 (0.2)</td>
<td>5 (0.3)</td>
<td>23 (0.3)</td>
<td>0.35</td>
</tr>
<tr>
<td>Excessive alcohol drinking</td>
<td>27 (0.8)</td>
<td>5 (0.3)</td>
<td>57 (0.8)</td>
<td>0.09</td>
</tr>
<tr>
<td>Received chemotherapy</td>
<td>79 (2.3)</td>
<td>43 (3.0)</td>
<td>142 (2.1)</td>
<td>0.16</td>
</tr>
<tr>
<td>Received steroid</td>
<td>651 (19.0)</td>
<td>308 (21.5)</td>
<td>1,254 (18.5)</td>
<td>0.05</td>
</tr>
<tr>
<td>Received NSAIDs</td>
<td>940 (27.4)</td>
<td>370 (25.8)</td>
<td>1,563 (23.1)</td>
<td>0.25</td>
</tr>
</tbody>
</table>

Note: *Capitation pays a physician or group of physicians a set amount for each enrolled person assigned to them, per period of time, whether or not that person seeks care.

Abbreviations: CCI, Charlson Comorbidity Index; CDHP, consumer-directed health plan; EBGS, electrical bone growth stimulation; EPO, exclusive provider organization; HMO, health maintenance organization; LIPUS, low-intensity pulsed ultrasound stimulation; No-stim, other non-stimulation fracture management interventions; NSAIDs, non-steroidal anti-inflammatory drugs; POS, point of service; PPO, preferred provider organization.

Differences for categorical variables; and a non-parametric Wilcoxon test was used to detect differences for CCI scores and health care and fracture-related costs. A generalized linear regression model (GLM) assuming gamma distribution and log link function was utilized to compare the total and fracture-related health care costs between treatment cohorts while controlling for between-cohort differences in patient demographics and baseline clinical characteristics. Because it is difficult to interpret the log-transformed regression coefficients from the GLM, predicted health care costs and the marginal effect of treatment were estimated. Specifically, the predicted costs for EBGS were estimated by applying the regression coefficients derived from the GLM to the covariates included in the model, and setting
EBGS to 1 and LIPUS to 0 while other covariates remained constant. Similarly, the predicted costs for LIPUS treatment were estimated by setting EBGS to 0 and LIPUS to 1, while the predicted costs for No-stim treatment were estimated by setting both EBGS and LIPUS to 0. An analysis of the marginal effects of treatment demonstrated how total and fracture-related health care costs are predicted to change as treatment changes from No-stim to EBGS to LIPUS.

**Results**

Among the commercially insured individuals in the dataset, 57,336 patients had at least one claim for fracture nonunion from July 2006 to September 2009. After applying the inclusion/exclusion criteria, 11,628 patients were selected for further study analysis (Figure 1): 3430 patients (29.5%) were in the EBGS cohort, 1434 patients (12.3%) were in the LIPUS cohort, and 6764 patients (58.2%) were in the No-stim cohort.

Basic patient demographics found that the average patient age was 45.4 years old (standard deviation: 13.4), 45.7% were males, 67.0% were enrolled in preferred provider organization plans, and 42.7% resided in the southern United States. Overall, the EBGS and LIPUS cohorts were similar in the distribution of age, gender, and type of patient insurance plan. However, both stimulation cohorts had more female patients and a higher average age than the No-stim cohort (Table 1).

Patients within the different treatment groups were also evaluated for fracture risk factors and comorbidities as these factors have been previously shown to have a negative impact on the success of bone healing. Diabetes was the most common condition among the comorbidities associated with increased risk of fracture nonunion (Table 1). The proportion of patients with diabetes was significantly higher in the EBGS cohort when compared to the No-stim cohort (14.0% vs 11.0%, \( P < 0.01 \)), but was not significantly different between the EBGS and LIPUS cohorts (14.0% vs 12.8%, \( P = 0.26 \)). The proportion of patients receiving non-steroidal anti-inflammatory drugs was significantly higher in the EBGS cohort (27.4% vs 23.1%, \( P < 0.01 \)) and the LIPUS cohort (25.8% vs 23.1%, \( P = 0.03 \)) when compared to the No-stim cohort. In addition, both the EBGS (CCI = 0: 69.8% vs 74.3%, \( P < 0.01 \)) and the LIPUS (CCI = 0: 70.6% vs 74.3%, \( P = 0.01 \)) cohorts were less likely to have low CCI scores when compared to the No-stim cohort.

Basic fracture characteristics found that tarsal and metatarsal fractures were the most common nonunion fractures treated; the average time between initial fracture and nonunion diagnosis was 130–136 days; and 3.6% of the initial fractures were open fractures. The No-stim cohort had a significantly higher proportion of patients with open fractures than the EBGS (4.4% vs 2.7%, \( P < 0.01 \)) and the LIPUS (4.4% vs 1.8%, \( P < 0.01 \)) cohorts (Table 2). Additionally, although the EBGS and LIPUS cohorts had a comparable distribution of fractures treated by bone location (\( P = 0.17 \)), the distribution was significantly different when compared to the No-stim cohort (both \( P < 0.01 \)).

In the 9 months prior to the index date, the EBGS and LIPUS cohorts had a similar number of fracture-related interventions (60.1% vs 57.5%, \( P = 0.10 \)). The No-stim cohort, however, had significantly fewer fracture-related interventions compared to either the EBGS (60.1% vs 48.0%, \( P < 0.01 \)) or the LIPUS (57.5% vs 48.0%, \( P < 0.01 \)) cohorts (Table 2). The most common fracture-related treatment was the application of a cast/splint. The EBGS and LIPUS cohorts had significantly more patients receiving a cast/splint to manage their fractures than the No-stim cohort (EBGS vs No-stim: 32.3% vs 24.3%, \( P < 0.01 \); LIPUS vs No-stim: 31.0% vs 24.3%, \( P < 0.01 \)). Open reduction with internal fixation was the most common invasive treatment. The EBGS and LIPUS cohorts had a similar proportion of open reduction procedures (20.8% vs 19.1%, \( P = 0.19 \)). However, both had a significantly higher proportion of open reduction procedures compared to the No-stim cohort (EBGS vs No-stim: 20.8% vs 14.5%, \( P < 0.01 \); LIPUS vs No-stim: 19.1% vs 14.5%, \( P < 0.01 \)).

During the 12-month post-index period, the proportion of fracture-related procedures was significantly less in the EBGS cohort than in the No-stim (33.6% vs 60.3%, \( P < 0.01 \)) and LIPUS (33.6% vs 42.2%, \( P < 0.01 \)) cohorts. Additionally, the LIPUS cohort also had significantly fewer fracture-related interventions when compared to the No-stim cohort (42.2% vs 60.3%, \( P < 0.01 \)) (Table 2). Bone grafting was the most common fracture-related treatment in the post-index period. The proportion of patients that underwent bone grafting procedures was significantly lower in the EBGS cohort than in the LIPUS (16.2% vs 22.2%, \( P < 0.01 \)) or the No-stim (16.2% vs 31.8%, \( P < 0.01 \)) cohorts. Similarly, the LIPUS cohort had significantly fewer patients treated by bone grafting procedures when compared to the No-stim cohort (22.2% vs 31.8%, \( P < 0.01 \)). The other documented non-stimulation fracture management interventions included cast/splint, application of external fixation device, closed reduction with and without internal fixation, open reduction with and without internal fixation, and arthroscopy.

The total health care costs in the 9 months prior to the index date were significantly higher in the EBGS
Table 2 Characteristics of fracture-related treatments in the different treatment cohorts

<table>
<thead>
<tr>
<th>Treatment in 9 months before index date</th>
<th>EBGS (N = 3,430)</th>
<th>LIPUS (N = 1,434)</th>
<th>No-stim (N = 6,764)</th>
<th>P-values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Days between first fracture claim and nonunion, mean (SD)</td>
<td>135 (75)</td>
<td>136 (78)</td>
<td>130 (88)</td>
<td>0.50</td>
</tr>
<tr>
<td>Open fracture, N (%)</td>
<td>93 (2.7)</td>
<td>26 (1.8)</td>
<td>299 (4.4)</td>
<td>0.06</td>
</tr>
<tr>
<td>Fracture location, N (%)</td>
<td>Clavicle</td>
<td>207 (6.0)</td>
<td>96 (6.7)</td>
<td>565 (8.4)</td>
</tr>
<tr>
<td>Humerus</td>
<td>180 (5.2)</td>
<td>65 (4.5)</td>
<td>431 (6.4)</td>
<td></td>
</tr>
<tr>
<td>Radius and ulna</td>
<td>210 (6.1)</td>
<td>97 (6.8)</td>
<td>688 (10.2)</td>
<td></td>
</tr>
<tr>
<td>Carpal</td>
<td>261 (7.6)</td>
<td>107 (7.5)</td>
<td>993 (14.7)</td>
<td></td>
</tr>
<tr>
<td>Metacarpal</td>
<td>47 (1.4)</td>
<td>8 (0.6)</td>
<td>146 (2.2)</td>
<td></td>
</tr>
<tr>
<td>Phalanges of hand</td>
<td>29 (0.8)</td>
<td>11 (0.8)</td>
<td>363 (5.4)</td>
<td></td>
</tr>
<tr>
<td>Neck of femur</td>
<td>35 (1.0)</td>
<td>13 (0.9)</td>
<td>213 (3.1)</td>
<td></td>
</tr>
<tr>
<td>Other parts of femur</td>
<td>78 (2.3)</td>
<td>47 (3.3)</td>
<td>163 (2.4)</td>
<td></td>
</tr>
<tr>
<td>Tibia and fibula</td>
<td>332 (9.7)</td>
<td>160 (11.2)</td>
<td>374 (5.5)</td>
<td></td>
</tr>
<tr>
<td>Ankle</td>
<td>275 (8.0)</td>
<td>133 (9.3)</td>
<td>690 (10.2)</td>
<td></td>
</tr>
<tr>
<td>Tarsal and metatarsal bones</td>
<td>1,661 (48.4)</td>
<td>645 (45.0)</td>
<td>1,609 (23.8)</td>
<td></td>
</tr>
<tr>
<td>Phalanges of foot</td>
<td>76 (2.2)</td>
<td>33 (2.3)</td>
<td>263 (3.9)</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>39 (1.1)</td>
<td>19 (1.3)</td>
<td>266 (3.9)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Treatment in 12 months after index date</th>
<th>EBGS (N = 3,430)</th>
<th>LIPUS (N = 1,434)</th>
<th>No-stim (N = 6,764)</th>
<th>P-values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any fracture-related treatment, N (%)</td>
<td>2,061 (60.1)</td>
<td>825 (57.5)</td>
<td>3,244 (48.0)</td>
<td>0.10</td>
</tr>
<tr>
<td>Cast/splint</td>
<td>1,107 (32.3)</td>
<td>444 (31.0)</td>
<td>1,645 (24.3)</td>
<td>0.37</td>
</tr>
<tr>
<td>Application of external fixation device</td>
<td>107 (3.1)</td>
<td>64 (4.5)</td>
<td>188 (2.8)</td>
<td>0.02</td>
</tr>
<tr>
<td>Closed reduction without internal fixation</td>
<td>152 (4.4)</td>
<td>69 (4.8)</td>
<td>290 (4.3)</td>
<td>0.56</td>
</tr>
<tr>
<td>Closed reduction with internal fixation</td>
<td>58 (1.7)</td>
<td>31 (2.2)</td>
<td>213 (3.1)</td>
<td>0.26</td>
</tr>
<tr>
<td>Open reduction without internal fixation</td>
<td>421 (12.3)</td>
<td>148 (10.3)</td>
<td>590 (8.7)</td>
<td>0.05</td>
</tr>
<tr>
<td>Open reduction with internal fixation</td>
<td>712 (20.8)</td>
<td>274 (19.1)</td>
<td>982 (14.5)</td>
<td>0.19</td>
</tr>
<tr>
<td>Bone graft</td>
<td>80 (2.3)</td>
<td>39 (2.7)</td>
<td>103 (1.5)</td>
<td>0.43</td>
</tr>
<tr>
<td>Arthroscopy</td>
<td>83 (2.4)</td>
<td>45 (3.1)</td>
<td>144 (2.1)</td>
<td>0.15</td>
</tr>
</tbody>
</table>

Notes: *Overall values indicate the total number of patients receiving some fracture-related treatment. The treatment groups detail the incidence of the individual treatments. Some patients may have received more than one treatment.

Abbreviations: EBGS, electrical bone growth stimulation; LIPUS, low-intensity pulsed ultrasound stimulation; No-stim, other non-stimulation fracture management interventions; SD, standard deviation.

(mean: $16,749; median: $7824) and LIPUS (mean: $19,441; median: $8574) cohorts than in the No-stim cohort (mean: $16,360; median: $5548) (both P < 0.01). However, total health care costs were not significantly different between the EBGS and LIPUS cohorts (P = 0.12) (Table 3). Outpatient care, the biggest component of the total health care costs, was significantly higher in the EBGS cohort (mean: $8159; median: $3967) (both P < 0.01). Fracture-related health care costs in the pre-index period were the highest in the LIPUS cohort (mean: $8749; median: $1089) followed by the EBGS (mean: $7392; median: $1223) and No-stim (mean: $7129; median: $893) cohorts (all pair-wise comparisons; P < 0.01) (Table 3). Inpatient stays were the highest portion of the fracture-related health care costs in the pre-index period. Pre-index fracture-related inpatient costs were significantly higher in the LIPUS cohort (mean: $6258; median: $0) than in the EBGS (mean: $4726; median: $0) (P = 0.02) and No-stim
<table>
<thead>
<tr>
<th>Treatment cohorts</th>
<th>Costs in 9 months before index date ($)</th>
<th>Costs in 12 months after index date ($)</th>
<th>P-values</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total health care costs</td>
<td>Total health care costs</td>
<td></td>
</tr>
<tr>
<td></td>
<td>EBGS (N = 3,430)</td>
<td>LIPUS (N = 1,434)</td>
<td>No-stim</td>
</tr>
<tr>
<td></td>
<td>Mean Standard error Median</td>
<td>Mean Standard error Median</td>
<td>EBGS vs</td>
</tr>
<tr>
<td></td>
<td>16,749 716  7,824</td>
<td>19,441 1,048  8,574</td>
<td>LIPUS</td>
</tr>
<tr>
<td></td>
<td>6,051 639  8,168 754</td>
<td>6,801 348  0</td>
<td>No-stim</td>
</tr>
<tr>
<td></td>
<td>9,146 209  9,789 492</td>
<td>8,159 229  3,967</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cost of inpatient admissions</td>
<td>Cost of inpatient admissions</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1,551 57  1,484 161</td>
<td>1,401 45  139</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cost of outpatient services</td>
<td>Cost of outpatient services</td>
<td></td>
</tr>
<tr>
<td></td>
<td>4,726 625  6,258 693</td>
<td>4,974 304  0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2,666 77  2,491 149</td>
<td>2,155 52  799</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fracture-related health care costs</td>
<td>Fracture-related health care costs</td>
<td></td>
</tr>
<tr>
<td></td>
<td>EBGS (N = 3,430)</td>
<td>LIPUS (N = 1,434)</td>
<td>No-stim</td>
</tr>
<tr>
<td></td>
<td>Mean Standard error Median</td>
<td>Mean Standard error Median</td>
<td>EBGS vs</td>
</tr>
<tr>
<td></td>
<td>7,392 639  1,223</td>
<td>8,749 737  1,089</td>
<td>LIPUS</td>
</tr>
<tr>
<td></td>
<td>4,726 625  6,258 693</td>
<td>4,974 304  0</td>
<td>No-stim</td>
</tr>
<tr>
<td></td>
<td>2,666 77  2,491 149</td>
<td>2,155 52  799</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cost of inpatient admissions</td>
<td>Cost of inpatient admissions</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1,551 57  1,484 161</td>
<td>1,401 45  139</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cost of outpatient services</td>
<td>Cost of outpatient services</td>
<td></td>
</tr>
<tr>
<td></td>
<td>4,726 625  6,258 693</td>
<td>4,974 304  0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2,666 77  2,491 149</td>
<td>2,155 52  799</td>
<td></td>
</tr>
</tbody>
</table>

**Note:** All costs presented are in US dollars and represent raw, unadjusted costs observed in the medical claims dataset.

**Abbreviations:** EBGS, electrical bone growth stimulation; LIPUS, low-intensity pulsed ultrasound stimulation; No-stim, other non-stimulation fracture management interventions.
(mean: $4974; median: $0) (P < 0.01) cohorts. Additionally, the costs for fracture-related outpatient services were significantly higher in the EBGS (mean: $2666; median: $1072) and LIPUS (mean: $2491; median: $919) cohorts when compared to the No-stim (mean: $2155; median: $799) cohort (both P < 0.01).

During the year following the first nonunion diagnosis, the total health care costs for the EBGS cohort (mean: $20,743; median: $11,233) were significantly lower than the costs for the LIPUS cohort (mean: $23,271; median: $12,456) (P < 0.01), but not significantly different from that of the No-stim cohort (mean: $24,315; median: $12,255) (P = 0.81) (Table 3). The inpatient costs were the lowest in the EBGS cohort (mean: $4746; median: $0), followed by the LIPUS (mean: $6526; median: $0) and then the No-stim (mean: $9182; median: $0) cohorts (all pair-wise comparisons: P < 0.01).

The fracture-related costs in the 12 months after the index date were the lowest in the EBGS cohort (mean: $8103; median: $4075), followed by the LIPUS (mean: $9777; median: $4309) and the No-stim (mean: $10,984; median: $4769) cohorts (all pair-wise comparisons: P < 0.01). Similarly, the fracture-related inpatient costs were the lowest in the EBGS cohort (mean: $2150; median: $0), followed by the LIPUS (mean: $3168; median: $0) and then the No-stim (mean: $5896; median: $0) cohorts (all pair-wise comparisons: P < 0.01). Conversely, the fracture-related outpatient costs (which includes device associated costs) were the lowest in the No-stim cohort (mean: $5088; median: $2937), followed by the EBGS (mean: $5952; median: $0) and LIPUS (mean: $6609; median: $4141) cohorts (all pair-wise comparisons: P < 0.01).

After controlling for demographics, CCI score, and fracture characteristics (open vs closed, treatments in the pre-index period, and fracture location), the EBGS cohort had significantly lower total health care (estimated regression coefficient = −0.087, P < 0.01) and fracture-related (estimated regression coefficient = −0.129, P < 0.01) costs in the 12 months following nonunion diagnosis when compared to the No-stim cohort; whereas patients in the LIPUS cohort had similar total health care (estimated regression coefficient = 0.005, P = 0.86) and fracture-related (estimated regression coefficient = −0.013, P = 0.71) costs to patients in the No-stim cohort (Table 4). Older age and higher CCI scores were associated with significantly higher total health care costs. Other factors associated with significantly higher total health care costs included living in the West region as compared to the South (estimated regression coefficient = 0.129, P < 0.01), receiving a cast/splint vs no cast/splint before nonunion diagnosis (estimated regression coefficient = 0.056, P = 0.01), receiving open reduction vs no open reduction (estimated regression coefficient = 0.095, P < 0.01), receiving other invasive treatments including bone graft, bone marrow aspiration, arthroscopy, amputation, or implant of recombinant bone morphogenetic protein vs not (estimated regression coefficient = 0.375, P < 0.01), and having a fracture in the arm (estimated regression coefficient = 0.170, P < 0.01) or the leg (estimated regression coefficient = 0.653, P < 0.01) vs in the foot. Similar patterns were found for fracture-related costs (Table 4).

Predicted total and fracture-related health care costs were generated based on the GLM and the regression coefficients generated in Table 4. The predicted total health care costs in the 12 months following nonunion diagnosis for the EBGS cohort ($21,632) were significantly lower than the No-stim ($23,843, marginal difference: −$2211, P < 0.01) and the LIPUS ($23,964, marginal difference: −$2332, P < 0.01) cohorts (Figure 2). Meanwhile, the marginal difference between the predicted total health care costs of the LIPUS and the No-stim cohorts was not significant ($121, P = 0.86). The predicted fracture-related health care costs in the 12-month post-index period for the EBGS cohort ($9100) were also significantly lower than the No-stim ($10,354, marginal difference: −$1253, P < 0.01) and the LIPUS ($10,225, marginal difference: −$1125, P < 0.01) cohorts. Alternatively, the predicted fracture-related costs for the LIPUS and the No-stim cohorts were not significantly different ($129, P = 0.71).

Discussion
In a commercially insured US population, the majority of the patients diagnosed with a fracture nonunion received No-stim treatment, despite the presence of clinical evidence supporting the efficacy and safety of EBGS and LIPUS. Preclinical studies have demonstrated that EBGS increases cellular proliferation and the expression of naturally occurring growth factors including bone morphogenetic proteins to help with the bone repair process. However, due to the device cost and the limited economic evidence to compare their cost-effectiveness to other fracture management practices, bone growth stimulators have often had insurance coverage limited to a subset of the approved indications within medical policy guidelines. Over the years, the Centers for Medicare and Medicaid Services (CMS) have revised the reimbursement policy for bone growth stimulators multiple times and recently, the Agency for Healthcare Research and Quality concluded that further evaluation with randomized
Table 4 Comparison of the total health care and fracture-related costs in the year following nonunion diagnosisa

<table>
<thead>
<tr>
<th>Treatment cohort (ref: No-stim)</th>
<th>Total health care costs</th>
<th>Fracture-related health care costs</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Estimated regression coefficient</td>
<td>Standard error</td>
</tr>
<tr>
<td>EBGS cohort</td>
<td>0.021</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>LIPUS cohort</td>
<td>0.028</td>
<td>0.86</td>
</tr>
<tr>
<td>Gender (ref: female)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>0.019</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Age (ref: 18–24)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age 25–34</td>
<td>0.039</td>
<td>0.76</td>
</tr>
<tr>
<td>Age 35–44</td>
<td>0.035</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Age 45–54</td>
<td>0.033</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Age 55–64</td>
<td>0.034</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Region (ref: South)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Northeast</td>
<td>0.031</td>
<td>0.61</td>
</tr>
<tr>
<td>North Central</td>
<td>0.022</td>
<td>0.13</td>
</tr>
<tr>
<td>West</td>
<td>0.025</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Unknown</td>
<td>0.064</td>
<td>0.05</td>
</tr>
<tr>
<td>Insurance plan type (ref: PPO)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Comprehensive</td>
<td>0.050</td>
<td>0.25</td>
</tr>
<tr>
<td>EPO</td>
<td>0.013</td>
<td>0.52</td>
</tr>
<tr>
<td>HMO</td>
<td>0.026</td>
<td>0.67</td>
</tr>
<tr>
<td>POS</td>
<td>0.032</td>
<td>0.39</td>
</tr>
<tr>
<td>CDHP</td>
<td>0.061</td>
<td>0.36</td>
</tr>
<tr>
<td>Missing/unknown</td>
<td>0.058</td>
<td>0.13</td>
</tr>
<tr>
<td>Charlson Comorbidity Index (CCI) (ref: CCI = 0)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CCI = 1</td>
<td>0.032</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>CCI = 2</td>
<td>0.029</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>CCI = 3 or higher</td>
<td>0.036</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Open fracture (ref: closed fracture)</td>
<td>0.049</td>
<td>0.45</td>
</tr>
<tr>
<td>Treatment received in pre-index period</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cast/splint (ref: no cast/splint)</td>
<td>0.021</td>
<td>0.01</td>
</tr>
<tr>
<td>Other invasive treatment (ref: no other invasive treatment)</td>
<td>0.036</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Close reduction (ref: no close reduction)</td>
<td>−0.025</td>
<td>0.24</td>
</tr>
<tr>
<td>Open reduction (ref: no open reduction)</td>
<td>0.026</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Location of fracture (ref: foot)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hand</td>
<td>0.029</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Arm</td>
<td>0.024</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Leg</td>
<td>0.029</td>
<td>&lt;0.01</td>
</tr>
</tbody>
</table>

Notes: The data presented in this table were used to generate the predicted health care costs presented in Figure 2; a the estimated regression coefficient is used as a measurement for how similar the group of interest is to the reference group. The closer to zero, the more similar the two groups are. Positive values indicate that the associated costs for the group of interest are greater than the reference group; negative values indicate that the associated costs for the group of interest are less than the reference group; b category combines POS with and without capitation due to small sample sizes; other invasive treatments include bone graft, bone marrow aspiration, arthroscopy, amputation, or implant of recombinant bone morphogenetic protein.

Abbreviations: CCI, Charlson Comorbidity Index; CDHP, consumer-directed health plan; EBGS, electrical bone growth stimulation; EPO, exclusive provider organization; HMO, health maintenance organization; LIPUS, low-intensity pulsed ultrasound stimulation; No-stim, other non-stimulation fracture management interventions; NSAIDs, non-steroidal anti-inflammatory drugs; POS, point of service; PPO, preferred provider organization.

controlled clinical trials is needed, particularly for patients aged 65 years old or older. CMS’s insurance coverage policy is often used as a guideline for commercial payers establishing their individual coverage policies and therefore is important to consider even for patients insured by commercial health care plans. Interestingly, while additional studies may further elucidate the benefits of bone growth stimulation, EBGS, unlike LIPUS, has existing randomized, placebo controlled nonunion studies demonstrating significantly improved healing of fracture nonunions with either capacitive coupling stimulation or pulsed electromagnetic field stimulation. Studies that compare EBGS to standard treatment practices may be helpful in supporting more extensive device coverage. Today, most commercial.
insurance plans offer coverage for EBGS devices to treat fracture nonunions. However, the coverage is often limited to certain bones and requires an elapsed timeframe before the device can be prescribed. Notably, this study is the first to compare actual health care utilization between EBGS, LIPUS, and No-stim treatment for fracture nonunions. Study results found that EBGS can offer significant cost-savings in the treatment of fracture nonunions when compared to both LIPUS and No-stim treatment.

Interestingly, in this study, prior to nonunion diagnosis (pre-index period), both the EBGS and LIPUS cohorts were more likely to receive fracture-related treatment, including application of external fixation devices, open reduction, or bone grafting, than the No-stim cohort, which suggests that the fractures in the stimulation cohorts were more severe and difficult to heal. In the 12 months following nonunion diagnosis, the pattern reversed, and the costs for the EBGS and the LIPUS cohorts were less than for the No-stim cohort, suggesting that stimulation treatment may be effective in managing nonunion fractures without the need for more invasive procedures. These differences in fracture management may explain the observed differences in health care costs between the different treatment cohorts. Specifically, the EBGS cohort had the lowest fracture-related costs in the 12 months following nonunion diagnosis and also the lowest costs due to inpatient admissions. The cost savings of EBGS were mainly driven by the higher savings associated with inpatient services. Notably, the fracture-related outpatient costs in the 12 months after nonunion diagnosis were significantly higher in both the EBGS and LIPUS groups when compared to the No-stim cohort. The costs of the stimulation devices, which averaged around $3000 (EBGS: mean: $2719, median: $2800; LIPUS: mean: $2626, median: $2765), were responsible for the higher outpatient costs. Interestingly, the cost savings in the outpatient services for the No-stim group were less than that required to cover the device cost, suggesting that the No-stim patients may have also required more non-device related outpatient care than the stimulation cohorts. Despite the initial cost of the stimulation device, this study shows that patients receiving bone growth stimulators actually incur less overall treatment costs by avoiding more expensive and invasive treatments.

Due to the differences in the pre-index fracture management practices between the different treatment cohorts, a sensitivity analysis was conducted to verify that the differences in pre-index fracture management did not have an effect on required post-index fracture management. For this analysis, patients were stratified by the presence of fracture-related inpatient stays in the pre-index period and compared for differences in post-index period health care costs. Among those patients without fracture-related inpatient stays in the pre-index period, LIPUS had significantly higher costs in the 1-year post-index period when compared to the EBGS cohort, although the costs between the No-stim and the EBGS cohorts were similar. Alternatively, among those patients with fracture-related inpatient stays in the pre-index period, No-stim incurred significantly higher costs than the EBGS cohort during the 1-year post-index period, while the costs between the LIPUS and the EBGS cohorts were comparable. This sensitivity analysis confirms that differences in pre-index fracture management did not impact the observed cost savings for EBGS in the post-index period as compared to the other treatment cohorts.

Previous research has shown through economic modeling that LIPUS used in combination with conservative treatment resulted in a cost savings of over $15,000 for patients with tibial fresh fractures. Cost savings in this model were mainly attributed to the avoidance of subsequent surgery and a reduction in workers’ compensation costs. Additionally,
part of the cost savings in the LIPUS study was attributed to a decrease in the rate of delayed unions. Alternatively, in this recent study of actual administrative claims, EBGS demonstrated an 11%–12% reduction in fracture-related costs compared to both LIPUS and No-stim treatment. The observed cost savings were likely due to less frequent invasive treatments required by patients in the EBGS cohort when compared to the LIPUS and No-stim cohorts. The cost savings reported in this study were not as substantial as those reported by Heckman et al because indirect medical costs, such as workers’ compensation and disability costs, which are not available in administrative claims, were not taken into account. Notably, this study included a broad range of nonunion fractures from different anatomical locations, and used administrative claims to more accurately reflect the real-world cost savings of EBGS for health care payers and provide a direct economic comparison of the different treatment techniques.

Study limitations
In administrative claims, nonunion diagnosis is not accompanied by the diagnosis of the specific fracture. To assess the characteristics of the initial fracture, we limited our analysis to patients with fractures at a single location. In addition, we were unable to identify the fracture severity using administrative claims. Alternatively, we used the post-initial fracture management data as an indicator for fracture severity. The incidence of soft tissue damage to nearby blood vessels and nerves, the development of post-traumatic wound infection, and the presence of traumatic compartment syndrome were also assessed. The prevalence of these conditions was generally very low (<1%) and comparable between the different treatment cohorts. For this study, the calculated fracture-related costs were based on claims for imaging procedures of bones and claims with diagnosis/treatment codes suggesting fracture, fracture nonunion, or malunion. It is possible that these claims may relate to diagnosis or treatment of other conditions. However, it is important to note that the identified limitations apply to all treatment cohorts and therefore would not create any bias toward a specific cohort that could impact the validity of the data analysis. Notably, this study measured actual health care resource utilization and did not assess healing time or the loss of work productivity in determining health care cost savings.

Conclusion
This is the first real-world study comparing the costs associated with the treatment of fracture nonunions between EBGS, LIPUS, and other fracture management practices (No-stim). Patients receiving EBGS for the treatment of fracture nonunions were less likely to undergo invasive procedures resulting in less health care resource use and cost savings to payers and patients. Patients receiving EBGS also had significantly less total and fracture-related costs in the year following nonunion diagnosis than patients receiving LIPUS or No-stim treatment. These study outcomes suggest that EBGS is a more cost-effective treatment for fracture nonunions when compared to both LIPUS and No-stim treatment.

Acknowledgments
The authors thank Nicole Benjamin and Alan Wang, United BioSource Corporation, Lexington, MA, USA and Lynne Coulter and Randy Graham, Biomet Spine and Bone Healing Technologies, Parsippany, NJ, USA for their contributions to this study and the preparation of this manuscript. Additionally, the authors thank Biomet Spine and Bone Healing Technologies, Parsippany, NJ, USA for providing funding support.

Disclosure
Ning Wu, Yuan-chi Lee, Teresa Wilcox, and Luke Boulanger are employees of United BioSource Corporation, which provides consulting and other research services to pharmaceutical, device, government, and non-government organizations. In their salaried positions, they work with a variety of companies and organizations, and were precluded from receiving payment or honoraria directly from these organizations for services rendered during the preparation of this manuscript. Daniel Segina is employed by Health First Physician Group and is a paid physician consultant by Biomet Spine and Bone Healing Technologies. Hallie Murray is an employee of Biomet Spine and Bone Healing Technologies, the study sponsor. The authors report no other conflicts of interest in this work.

References


